EGFR and central nervous system cancer: EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, afatinib, and dacomitinib, have been studied in EGFR-altered gliomas but have yielded minimal to no clinical benefit and short durations of response [10–14].